An association exists between weight gain and a decrease in responsivity of regions connected to taste and reward processing to palatable high-fat and high-fat/high-sugar food tastes, a study has shown. Moreover, avoiding weight gain can increase the sensitivity of taste, which then helps prevent future excessive weight gain.
An enzyme-linked immunosorbent assay (ELISA) is better at detecting glutamic acid decarboxylase antibodies (GADAb) than the previously utilized radioimmunoassay in childhood-onset type 1 diabetes mellitus (T1DM), a new study has found.
An association exists between body composition phenotypes and physical function in patients with chronic obstructive pulmonary disease (COPD), with sarcopaenic-obese (SO) patients being the most impaired, a study has shown.
The use of thiazides appears to contribute to an increased risk of stroke in patients with type 2 diabetes, specifically in those receiving intensive blood pressure (BP) control, a recent study has found.
Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.